不同抗菌药物治疗方案在急性胰腺炎治疗中的用药成本分析

发布时间：2018-08-03 11:47

【摘要】：目的观察和分析不同抗菌药物治疗方案在急性胰腺炎(AP)治疗中的用药成本,为合理制订临床治疗方案提供客观依据。方法选取2015年8月-2016年6月80例接受保守治疗的AP患者为研究对象,根据抗菌药物治疗方案将患者分为A组(应用拉氧头孢方案,27例)、B组(应用头孢哌酮/他唑巴坦方案,13例)、C组(应用奥硝唑+头孢他啶方案,9例)、D组(应用奥硝唑+拉氧头孢方案,18例)、E组(应用奥硝唑+头孢哌酮/他唑巴坦方案,13例);对5组患者的疗效分布、治愈率、临床有效率进行评价和比较。结果 5组患者的疗效分布、治愈率、临床有效率比较差异均无统计学意义;C组患者的日均抗菌药物费用低于其他各组,差异有统计学意义(P0.05),假设药价下降10.0%进行敏感度检测,C组患者的日均抗菌药物费用仍低于其他各组,差异均有统计学意义(P0.05)。结论在AP治疗中,不同抗菌药物治疗方案可获得基本相当的治疗效果,应用奥硝唑+头孢他啶治疗方案能够在保证治疗效果的前提下付出最小的用药成本。
[Abstract]:Objective to observe and analyze the cost of different antimicrobial regimens in the treatment of acute pancreatitis (AP) so as to provide an objective basis for rational clinical treatment. Methods from August 2015 to June 2016, 80 patients with AP receiving conservative treatment were selected as subjects. Patients were divided into two groups: group A (27 cases with lacticocefin) and group B (13 cases with cefoperazone / tazobactam) and group C (9 cases with ornidazole ceftazidime). Group E (13 cases with ornidazole cefoperazone / tazobactam regimen); The cure rate and clinical effective rate were evaluated and compared. Results there was no significant difference in the distribution of curative effect, cure rate and clinical effective rate among the five groups. The average daily antimicrobial cost in group C was lower than that in other groups. The difference was statistically significant (P0.05), assuming that the drug price decreased by 10.0% in the sensitivity test group C patients were still lower than the other groups, the differences were statistically significant (P0.05). Conclusion in the treatment of AP, different antimicrobial regimens can achieve similar therapeutic effects, and ornidazolceftazidime can pay the minimum cost under the premise of ensuring the therapeutic effect.
【作者单位】：武警浙江总队嘉兴医院药械科;
【基金】：浙江省卫生厅科学研究计划B类基金资助项目(09006455)
【分类号】：R576

【参考文献】